Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 22Phase 1/2 13Phase 3 5Phase 4 2Phase NA 1Phase 2/3 1

Status

Unknown 2Terminated 2Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 89Leukemia 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma 26Leukemia, Erythroblastic, Acute 19Leukemia, Myelomonocytic, Acute 18Leukemia, Monocytic, Acute 18Leukemia, Megakaryoblastic, Acute 18Congenital Abnormalities 13Burkitt Lymphoma 13Lymphoma, Large B-Cell, Diffuse 12Myelodysplastic Syndromes 10Lymphoma, Non-Hodgkin 10Anemia, Refractory, with Excess of Blasts 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Follicular 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Eosinophilic, Acute 6Recurrence 5Myeloproliferative Disorders 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Promyelocytic, Acute 5Leukemia, Biphenotypic, Acute 5Leukemia, Basophilic, Acute 5Hodgkin Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Multiple Myeloma 4

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Cytarabine × Clear all
NCT03765541 2025-04-10

DEXAML-03

University Hospital, Toulouse

Phase 3 Terminated
73 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Shanxi Bethune Hospital

Phase 3 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02298166 2021-10-06

Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations

University of Ulm

Phase 3 Terminated
9 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT01449344 2017-03-07

(R-HAD)

European Mantle Cell Lymphoma Network

Phase 3 Unknown
128 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡